Search

Arcascope, a leading digital health company specializing in sleep and circadian medicine, recently became the most recent company to join the MSK Innovation Hub in October 2024.

… Friday, January 3, 2025 Arcascope, a leading digital health company specializing in sleep and circadian medicine, recently became the most recent company to join the MSK Innovation Hub in October 2024. Arcascope will pilot test Arcasync, an app for monitoring and managing sleep and circadian rhythms

MSK investigators presented new research on a range of important topics at the 2024 Annual Meeting of the American Association for Cancer Research.

… Tuesday, April 9, 2024 Researchers from Memorial Sloan Kettering Cancer Center (MSK) presented new research on a range of important topics at the 2024 Annual Meeting of the American Association for Cancer Research (AACR). Among the dozens of studies reported were a clinical trial that evaluated a new

Memorial Sloan Kettering President Craig Thompson, his wife, scientist Tullia Lindsten, and husband-and-wife physician-scientists Yu Chen and Ping Chi, discuss the pleasures and challenges of dual-career marriages.

… Monday, December 23, 2013 On Thursday, November 20, 2013, Gerstner Sloan Kettering Women in Science sat down to lunch with Memorial Sloan Kettering President and CEO Craig B. Thompson  and his wife, scientist  Tullia Lindsten , along with married physician-scientists Yu Chen and Ping Chi . They were

Memorial Sloan Kettering’s partnership in a pioneering effort to speed the development of cancer immunotherapies drew national headlines.

… Friday, December 6, 2013 Summary Memorial Sloan Kettering’s partnership in a pioneering effort to speed the development of cancer immunotherapies drew national headlines. A pioneering effort to speed the development of novel immunotherapies for cancer drew national headlines this week with the announcement

Sequencing circulating tumor cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) improved diagnosis, decision-making, and clinical care in pediatric and adolescent and young adult (AYA) patients with brain tumors.

… Friday, June 17, 2022 Sequencing circulating tumor cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) improved diagnosis, decision-making, and clinical care in pediatric and adolescent and young adult (AYA) patients with brain tumors, according to clinical experience at Memorial Sloan Kettering Cancer

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan Kettering Cancer Center and colleagues at other cancer centers have published their findings in the August 26 edition of the New England Journal of Medicine.

… Wednesday, August 25, 2010 A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma . Investigators at Memorial Sloan Kettering Cancer Center and colleagues

… Monday, November 9, 2020 Miriam Lorena Murray estaba en la mejor condición física de su vida cuando recibió una desgarradora noticia: su médico le diagnosticó, cáncer de mama. “Estaba en un estado dos ya pasando a un estado tres y sin ningún síntoma, viéndome espectacular”, contó Miriam Lorena de 50

Overall survival (OS) for patients with melanoma brain metastasis treated at Memorial Sloan Kettering Cancer Center has increased significantly over the past five years, up to 13 months, according to our research published recently in Cancer.

… Thursday, November 18, 2021 Overall survival (OS) for patients with melanoma brain metastasis treated at Memorial Sloan Kettering Cancer Center has increased significantly over the past five years, up to 13 months, according to our research published recently in Cancer .  (1) This increased OS duration

The first-ever clinical trial at MSK to evaluate a novel CAR T cell therapy for AML is showing promise.

… Friday, August 29, 2025 Chimeric antigen receptor (CAR) T cell therapies have changed the way that many blood cancers are treated. A type of immunotherapy, CAR T cells redirect a patient’s own immune system in the fight against cancer. Memorial Sloan Kettering Cancer Center (MSK) has been a leader in

The funding will support patient navigation, essential needs, telemedicine, and psychosocial support services, including language translation and interpretation.

… Wednesday, September 21, 2022 The Immigrant Health and Cancer Disparities Service (IHCD) at Memorial Sloan Kettering Cancer Center (MSK) has received a five-year grant that will help advance health equity in New York and beyond. The grant, from the Merck Foundation as part of its Alliance for Equity